1. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burrell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): S1–113.
2. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professional. Circulation 1991; 83: 356–362.
3. Lakier JB. Smoking and cardiovascular diseases. The American Journal of Medicine 1992; 93(Suppl 1): S8–12.
4. Njølstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmarks Study. Circulation 1996; 93: 450–456. Doi 10.1161/01.CIR.93.3.450.
5. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005; 111(20): 2684–2698.
6. Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis 2003; 46: 11–29.
7. Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995; 91: 1749–1756.
8. Hung J, Lam JYT, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet trombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432–2436.
9. Ardulaki KA, Walker NM, Day NE, et al. Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. Br J Surg 2000; 87: 195–200.
10. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003; 46: 91–111.
11. Castela S, Duarte R, Reis RP, Correia MJ, Toste J, Carmelo V, Cardim N, Adao M, Correia JM. Acute coronary syndromes in smokers: clinical and angiographic characteristics. Rev Port Cardiol 2004; 23(5): 697–705.
12. Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, Stone GW. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction – the smoker’s paradox revisited. Am Heart J 2005; 150(2): 358–364.
13. Grundtvig M, Hagen TP, German M, Reikvam A. Sex-based differences in premature first myocardial infarction caused by smoking: twice as many years lost by women as by men. Eur J Cardiovasc Prev Rehabil 2009; 16(2): 174–179.
14. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years‘ observations on male British doctors. BMJ 2004; 328(7455): 1519.
15. Hawkins BT, Brown RC, Davis TP. Smoking and ischemic stroke: a role for nicotine? Trends in Pharmacological Sciences 3/2002; 23(2): 78–82.
16. Lu M, Ye Q, Adami HO, Weiderpass E. Stroke incidence in women under 60 years of age related to alkohol intake and smoking habit. Cerebrovas Dis 2008; 25(6): 517–525.
17. Colditz GA, Bonita R, Stampfer MJ, et al. Cigarette smoking and risk of stroke in middle-aged women. J Engl J Med 1988; 318: 937–941.
18. Bhat VM, Cole JW, Sorkin JD, Wozniak MA, Malarcher AM,Ciles WH, Stern BJ, Kittner SJ. Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke 2008; 39(9): 2439–2443.
19. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
20. Tobacco Advisory Group, Royal College of Physicians. Nicotine Addiction in Britain. London: Royal College of Physicians 2000.
21. Arnsten JH. Treatment of nicotine dependence in the primary care setting. Primary Psychiatry 1996; 3(9): 27–30.
22. Britt JP, McGehee DS. Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. J Neurosci 2008; 28(7): 1672–1678.
23. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, May 2008.
24. Cahill K, Stead LF, Lancaster T. Nicotine partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103.
25. Sobieraj DM, White WB, Baker WL. Cardiovascular effects of pharmacologic therapies for smoking cessation. J Am Soc Hypertens 2013; 7(1): 61–67.
26. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Can Med Assoc J 2011; 183: 1359 –1366.
27. Samuels L. Varenicline: cardiovascular safety. CMAJ 2011; 183(12): 1407–1408.
28. Hays TJ. Varenicline for smoking cessation: Is it a heartbreaker? CMAJ 2011; 183(12): 1346–1347.
29. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Response to letter regarding article “Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial“. Circulation 2012; 122: e446.
30. Hays TJ, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2012; 70(18): 2357–2372.
31. Responses to the article „Singh, S, et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and metaanalysis. Can Med Assoc J 2011; 183: 1359–1366.“ (citováno 2012-12-20) Dostupné z URL: http://www.cmaj.ca/content/early/2011/07/04/cmaj.110218.abstract/reply
32. U.S. Food and Drug Administration. FDA Drug Safety Communication: Chantix (varenicline) drug label now contains updated efficacy and safety information. 2011. Dostupné z URL: http: //www.fda.gov/Drugs/DrugSafety/ucm264436.htm
33. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856.
34. European Medicine Agency Press Release European Medicines Agency confirms positive benefit-risk balance for Champix. Benefits as a smoking-cessation medicine outweigh slight reported increase in cardiovascular events. Available: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001314.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true (accessed 2011 July 25).
35. Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012; 345: e7176.
36. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221–229.
37. Harrison-Woolrych M, Maggo S, Tan M, Savage R, Ashton J. Cardiovascular events in patients taking varenicline. A case series from intensive postmarketing surveillance in New Zealand, Drug Safety 2012; 35(1): 33–43.
38. Ware JH, Vetrovec GW, Miller AB, Van Tosh A, Gaffney M,Yunis C, Arteaga C, Borer JS. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. Am J Ther. 2013; 20(3): 235–246.
39. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review). Cochrane Database of Systematic Reviews 2013. DOI: 10.1002/14651858.CD009329.pub2.
40. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014; 129(1): 28–41. doi: 10.1161/CIRCULATIONAHA.113.003961. Epub 2013 Dec 9.